Tam Nguyen, DO
Internal Medicine · San Jose, CANPI 1962520478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,828, more than ten times the $80 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$1K
- Novo Nordisk$725
- AstraZeneca$702
- Nestle Healthcare Nutrition Inc.$654
- Scilex Pharmaceuticals Inc.$408
- plus $2K from 33 others
What the payments were for
- Food & beverage$7,19697%
- Education$2423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 68 | $1,665 |
| AbbVie(2 entities) | 47 | $1,087 |
| Novo Nordisk | 34 | $725 |
| AstraZeneca | 28 | $702 |
| Nestle Healthcare Nutrition Inc. | 35 | $654 |
| Scilex Pharmaceuticals Inc. | 21 | $408 |
| Kowa Pharmaceuticals America, Inc. | 8 | $184 |
| Boehringer Ingelheim | 7 | $180 |
| Aimmune Therapeutics, Inc. | 5 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $153 |
| Ironwood Pharmaceuticals, Inc | 6 | $141 |
| Abbott | 7 | $131 |
| Pfizer | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 |
| Bayer | 4 | $94 |
| Vivus LLC | 4 | $86 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| Lilly USA, LLC | 3 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| Sunovion Pharmaceuticals Inc. | 4 | $66 |
| Amarin Pharma, Inc. | 3 | $66 |
| Novartis | 3 | $64 |
| Gilead | 2 | $47 |
| Optinose US, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Oyster Point Pharma, Inc. | 1 | $31 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Redhill Biopharma Inc. | 1 | $26 |
| Medtronic | 1 | $26 |
| Agepha Pharma FZ LLC | 1 | $25 |
| Morphosys, US Inc. | 1 | $23 |
| Abiomed | 1 | $23 |
| Amgen | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Edwards Lifesciences | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,438 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 675 | $580,893 |
| ZenpepLipase/Protease/Amylase | 276 | $437,199 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 565 | $374,928 |
| RybelsusSemaglutide | 216 | $294,464 |
| FarxigaDapagliflozin Propanediol | 280 | $266,372 |
| JanuviaSitagliptin Phosphate | 316 | $250,930 |
| EliquisApixaban | 176 | $179,634 |
| GemtesaVibegron | 196 | $151,696 |
| LinzessLinaclotide | 147 | $128,460 |
| VraylarCariprazine Hcl | 67 | $110,655 |
| Icosapent Ethyl | 266 | $100,115 |
| RestasisCyclosporine | 139 | $98,005 |
| VascepaIcosapent Ethyl | 194 | $90,680 |
| OzempicSemaglutide | 70 | $79,808 |
| XareltoRivaroxaban | 66 | $57,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $180 | $624,760750 claims |
| Aimmune Therapeutics, Inc.Zenpep | $157 | $437,199276 claims |
| GSKTrelegy Ellipta, Arexvy | $1,665 | $386,347604 claims |
| Novo NordiskRybelsus, Ozempic | $725 | $374,273286 claims |
| AbbVieLinzess, Vraylar, Restasis | $1,087 | $337,120353 claims |
| AstraZenecaFarxiga | $702 | $266,372280 claims |
| PfizerEliquis, Nurtec Odt | $105 | $207,121191 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $81 | $151,696196 claims |
| Lilly USA, LLCTrulicity | $76 | $42,00537 claims |
| GileadVemlidy | $47 | $30,43022 claims |
| NovartisEntresto | $64 | $22,33520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Jose
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.